Greenyn Biotechnology Co (ROCO:6846) Operating Margin %: 22.66% (As of Dec. 2025) — Near Median


ROCO:6846 Greenyn Biotechnology Co Ltd ROCO:6846
65 GF Score
Price NT$63.70
GF Value NT$66.84
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Greenyn Biotechnology Co Operating Margin %?

Greenyn Biotechnology Co ROCO:6846 -0.47% 65 Operating Margin % is 22.66% as of Dec. 2025, which is 2% above its 10-year median of 22.20. GuruFocus rates ROCO:6846 with a GF Score™ of 65/100 and a GF Value™ of NT$66.84 (Fairly Valued). The stock has 6 warning signs investors should review. Among 944 Biotechnology companies, Greenyn Biotechnology Co ranks better than 88.67% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Greenyn Biotechnology Co's Operating Income for the three months ended in Dec. 2025 was NT$60.8 Mil. Greenyn Biotechnology Co's Revenue for the three months ended in Dec. 2025 was NT$268.3 Mil. Therefore, Greenyn Biotechnology Co's Operating Margin % for the quarter that ended in Dec. 2025 was 22.66%.

Warning Sign:

Greenyn Biotechnology Co Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -4.6%.

The historical rank and industry rank for Greenyn Biotechnology Co's Operating Margin % or its related term are showing as below:

ROCO:6846' s Operating Margin % Range Over the Past 10 Years
Min: 19.22   Med: 22.2   Max: 24.38
Current: 20.63


ROCO:6846's Operating Margin % is ranked better than
88.67% of 944 companies
in the Biotechnology industry
Industry Median: -86.83 vs ROCO:6846: 20.63

Greenyn Biotechnology Co's 5-Year Average Operating Margin % Growth Rate was -4.60% per year.

Greenyn Biotechnology Co's Operating Income for the three months ended in Dec. 2025 was NT$60.8 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was NT$188.8 Mil.


Greenyn Biotechnology Co  (ROCO:6846) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Greenyn Biotechnology Co Operating Margin % Related Terms


Greenyn Biotechnology Co Operating Margin % Historical Data

* Premium members only.

The historical data trend for Greenyn Biotechnology Co's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Greenyn Biotechnology Co Operating Margin % Chart

Greenyn Biotechnology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial 24.38 23.63 20.09 19.22 20.63

Greenyn Biotechnology Co Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.86 24.33 17.08 17.38 22.66

ROCO:6846 vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Greenyn Biotechnology Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Greenyn Biotechnology Co Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Greenyn Biotechnology Co's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Greenyn Biotechnology Co's Operating Margin % falls into.


ROCO:6846
65GF Score
Greenyn Biotechnology Co Ltd ROCO:6846
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Greenyn Biotechnology Co Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Greenyn Biotechnology Co's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=188.81 / 915.321
=20.63 %

Greenyn Biotechnology Co's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=60.803 / 268.288
=22.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 22.66% mean?
Greenyn Biotechnology Co (ROCO:6846) has a Operating Margin % of 22.66% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Greenyn Biotechnology Co and its competitors. This is near median its historical median of 22.20. Over the past decade, Greenyn Biotechnology Co's Operating Margin % has ranged from 19.22 to 24.38. According to the industry distribution chart, Greenyn Biotechnology Co ranks #107 out of 944 companies in the Biotechnology industry, placing it in the top 11.3%.
Is Greenyn Biotechnology Co's Operating Margin % too high?
Greenyn Biotechnology Co's current Operating Margin % of 22.66% is near median its 10-year median of 22.20. Over the past 10 years, this metric has ranged from a low of 19.22 to a high of 24.38. Based on the distribution chart, Greenyn Biotechnology Co ranks #107 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Greenyn Biotechnology Co has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Greenyn Biotechnology Co's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Greenyn Biotechnology Co ranks #107 out of 944 companies for Operating Margin %. This places Greenyn Biotechnology Co in the top 11% of its industry — outperforming the majority of peers. Historically, Greenyn Biotechnology Co's own Operating Margin % has ranged from 19.22 to 24.38 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Greenyn Biotechnology Co and its competitors. Greenyn Biotechnology Co's current Operating Margin % is 22.66%, which is near median its own 10-year median of 22.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greenyn Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Greenyn Biotechnology Co (ROCO:6846) is currently considered Fairly Valued. The stock's GF Value™ is NT$66.84, compared to a current price of NT$63.70 — trading 4.7% below its estimated fair value. The current Operating Margin % is 22.66%, which is near median its 10-year median of 22.20. Greenyn Biotechnology Co's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Greenyn Biotechnology Co (ROCO:6846), the current Operating Margin % is 22.66% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Greenyn Biotechnology Co (ROCO:6846) Overvalued in 2026?

Based on GuruFocus' analysis, Greenyn Biotechnology Co stock appears to be undervalued. The current stock price of NT$63.70 is trading 4.7% below its estimated GF Value™ of NT$66.84. GuruFocus considers Greenyn Biotechnology Co to be Fairly Valued.

Key valuation signals for ROCO:6846:

  • Operating Margin %: 22.66% (near median its 10-year median of 22.20)
  • GF Value™: NT$66.84 vs. price of NT$63.70 (4.7% below fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the ROCO:6846 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Greenyn Biotechnology Co Business Description

Address No 43 Keya Road, 5th Floor, Daya District, Taichung, TWN
Greenyn Biotechnology Co Ltd is engaged in the business of health food raw materials production and sales of raw materials and production and sales of formula preparation.
65GF Score

Get the complete analysis for ROCO:6846

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$63.70
Price
NT$66.84
GF Value